Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Johnson & Johnson Reports Strong Phase 3 Results For Multiple Myeloma Therapy

Johnson & Johnson Inc. JNJ

On Thursday, Johnson & Johnson (NYSE:JNJ) announced positive topline results from a recent study.

The company’s Phase 3 MajesTEC-3 trial is evaluating Tecvayli (teclistamab-cqyv) in combination with Darzalex Faspro (daratumumab and hyaluronidase-fihj) for patients with relapsed or refractory multiple myeloma who received one to three prior treatments.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.